CO2023007527A2 - Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza - Google Patents

Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza

Info

Publication number
CO2023007527A2
CO2023007527A2 CONC2023/0007527A CO2023007527A CO2023007527A2 CO 2023007527 A2 CO2023007527 A2 CO 2023007527A2 CO 2023007527 A CO2023007527 A CO 2023007527A CO 2023007527 A2 CO2023007527 A2 CO 2023007527A2
Authority
CO
Colombia
Prior art keywords
antibodies against
neutralizing antibodies
against influenza
broadly neutralizing
influenza neuraminidase
Prior art date
Application number
CONC2023/0007527A
Other languages
English (en)
Spanish (es)
Inventor
Davide Corti
Elisabetta Cameroni
Matteo Samuele Pizzuto
Andrea Minola
Gyorgy Snell
Elena Ferri
Original Assignee
Humabs Biomed Sa
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Vir Biotechnology Inc filed Critical Humabs Biomed Sa
Publication of CO2023007527A2 publication Critical patent/CO2023007527A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CONC2023/0007527A 2020-11-23 2023-06-07 Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza CO2023007527A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117448P 2020-11-23 2020-11-23
US202063123424P 2020-12-09 2020-12-09
US202163197160P 2021-06-04 2021-06-04
US202163261463P 2021-09-21 2021-09-21
PCT/US2021/060155 WO2022109309A1 (en) 2020-11-23 2021-11-19 Broadly neutralizing antibodies against influenza neuraminidase

Publications (1)

Publication Number Publication Date
CO2023007527A2 true CO2023007527A2 (es) 2023-08-18

Family

ID=79021106

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007527A CO2023007527A2 (es) 2020-11-23 2023-06-07 Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza

Country Status (13)

Country Link
US (1) US20240092876A1 (https=)
EP (1) EP4247495A1 (https=)
JP (1) JP2023551668A (https=)
KR (1) KR20230137293A (https=)
AU (1) AU2021381778A1 (https=)
CA (1) CA3199023A1 (https=)
CL (1) CL2023001462A1 (https=)
CO (1) CO2023007527A2 (https=)
IL (1) IL302963A (https=)
MX (1) MX2023005654A (https=)
PH (1) PH12023551390A1 (https=)
TW (1) TW202229329A (https=)
WO (1) WO2022109309A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522295A (ja) * 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
AU2023358546A1 (en) * 2022-10-14 2025-05-29 Longhorn Vaccines And Diagnostics, Llc Vaccines and antibodies for the treatment and prevention of microbial infections
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7803C (https=)
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2016090170A1 (en) * 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US11254733B2 (en) * 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
AU2018334886B2 (en) 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
CA3096703A1 (en) * 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
WO2022109309A9 (en) 2022-09-01
KR20230137293A (ko) 2023-10-04
EP4247495A1 (en) 2023-09-27
AU2021381778A9 (en) 2025-01-09
CL2023001462A1 (es) 2023-10-20
IL302963A (en) 2023-07-01
CA3199023A1 (en) 2022-05-27
US20240092876A1 (en) 2024-03-21
MX2023005654A (es) 2023-07-31
PH12023551390A1 (en) 2023-12-04
AU2021381778A1 (en) 2023-06-22
TW202229329A (zh) 2022-08-01
WO2022109309A1 (en) 2022-05-27
JP2023551668A (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
CO2023007527A2 (es) Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
MX2020007888A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
CO7061039A2 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CL2025002872A1 (es) Anticuerpos anti-cd19 y estructuras car-t
MX2018013172A (es) Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
CL2024000091A1 (es) Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CO2022010244A2 (es) Anticuerpos anti-e-selectina, composiciones y métodos de uso
CO2021008774A2 (es) Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
MX2023005653A (es) Anticuerpos contra los virus de la influenza a.
AR124118A1 (es) Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza
AR130046A1 (es) Anticuerpos ampliamente neutralizantes contra los paramixovirus vsr y mpv
BR112021006345A2 (pt) anticorpos e método para tratamento de infecção por lyssavirus
CL2023000221A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
AR121129A1 (es) Anticuerpos anti-e-selectina, composiciones y métodos de uso
EA202190351A1 (ru) Композиция, входящая в состав вакцины против гриппа